1. Home
  2. ENTA vs SUUN Comparison

ENTA vs SUUN Comparison

Compare ENTA & SUUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.71

Market Cap

407.5M

Sector

Health Care

ML Signal

HOLD

SUUN

SolarBank Corporation

HOLD

Current Price

$1.58

Market Cap

59.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
SUUN
Founded
1995
2013
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.5M
59.0M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
SUUN
Price
$14.71
$1.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$20.40
$5.00
AVG Volume (30 Days)
288.3K
496.4K
Earning Date
11-17-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$65,324,000.00
$32,753,484.00
Revenue This Year
$0.99
$127.67
Revenue Next Year
$0.19
$4.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.09
$1.23
52 Week High
$15.34
$6.43

Technical Indicators

Market Signals
Indicator
ENTA
SUUN
Relative Strength Index (RSI) 67.09 44.94
Support Level $13.75 $1.56
Resistance Level $14.79 $1.72
Average True Range (ATR) 0.74 0.10
MACD -0.01 0.00
Stochastic Oscillator 90.89 21.02

Price Performance

Historical Comparison
ENTA
SUUN

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About SUUN SolarBank Corporation

SolarBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.

Share on Social Networks: